[Effect of new pyrazolo-(1,2-a)-1,2,5-triazepine derivatives on the central nervous system].
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D001381:Azepines / Q000494:pharmacology*; D004357:Drug Synergism; D006591:Hexobarbital / Q000494:pharmacology; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009043:Motor Activity / Q000187:drug effects*; D010433:Pentylenetetrazole / Q000009:adverse effects / Q000037:antagonists & inhibitors; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy*
D000927:Anticonvulsants; D001381:Azepines; D006993:Hypnotics and Sedatives; D011720:Pyrazoles; D006591:Hexobarbital; D010433:Pentylenetetrazole
Badania wpływu na ośrodkowy układ nerwowy nowych pochodnych pirazolo-(1,2-a)-1,2,5-triazepiny.